Other Publications (9)
- Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
- Critical Care Medicine
- Journal of the American Pharmacists Association : JAPhA
- Advances in Therapy
- The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
- The Annals of Pharmacotherapy
- American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
- ClinicoEconomics and Outcomes Research : CEOR
- American Journal of Pharmaceutical Education
Articles by Kem P. Krueger in JoVE
Rimozione di Oligoelementi per Cupric nanoparticelle di ossido di uranio da Jodi R. Schilz1, K. J. Reddy2, Sreejayan Nair3, Thomas E. Johnson4, Ronald B. Tjalkens5, Kem P. Krueger3, Suzanne Clark6 1Division of Physical Therapy, Department of Orthopedics & Rehabilitation, University of New Mexico, 2Department of Ecosystem Science and Management, University of Wyoming, 3School of Pharmacy, University of Wyoming, 4Department of Environmental and Radiological Health Sciences, Colorado State University, 5Center for Environmental Medicine, Colorado State University, 6College of Pharmacy, California Northstate University
Other articles by Kem P. Krueger on PubMed
Propylene Glycol Accumulation Associated with Continuous Infusion of Lorazepam in Pediatric Intensive Care Patients Critical Care Medicine. Dec, 2002 | Pubmed ID: 12483068 To determine if propylene glycol accumulates in children receiving continuous lorazepam infusion and, if accumulation occurs, to determine if it is associated with significant laboratory abnormalities.
Improving Adherence and Persistence: a Review and Assessment of Interventions and Description of Steps Toward a National Adherence Initiative Journal of the American Pharmacists Association : JAPhA. Nov-Dec, 2003 | Pubmed ID: 14717263 To identify the effectiveness of adherence interventions reported in the literature, to identify interventions being conducted and/or sponsored by large chain pharmacies and pharmaceutical manufacturers, and to seek input from a panel of pharmacists who address adherence issues on a daily basis as to the steps that should be taken to advance a national initiative to increase awareness of the importance of and opportunities associated with medication adherence and persistence.
Medication Adherence and Persistence: a Comprehensive Review Advances in Therapy. Jul-Aug, 2005 | Pubmed ID: 16418141 Estimates of adherence to long-term medication regimens range from 17% to 80%, and nonadherence (or nonpersistence) can lead to increased morbidity, mortality, and healthcare costs. Multifaceted interventions that target specific barriers to adherence are most effective, because they address the problems and reinforce positive behaviors. Providers must assess their patients' understanding of the illness and its treatment, communicate the benefits of the treatment, assess their patients' readiness to carry out the treatment plan, and discuss any barriers or obstacles to adherence that patients may have. A positive, supporting, and trusting relationship between patient and provider improves adherence. Individual patient factors also affect adherence. For example, conditions that impair cognition have a negative impact on adherence. Other factors--such as the lack of a support network, limited English proficiency, inability to obtain and pay for medications, or severe adverse effects or the fear of such effects--are all barriers to adherence. There are multiple reasons for nonadherence or nonpersistence; the solution needs to be tailored to the individual patient's needs. To have an impact on adherence, healthcare providers must understand the barriers to adherence and the methods or tools needed to overcome them. This report describes the barriers to medication adherence and persistence and interventions that have been used to address them; it also identifies interventions and compliance aids that practitioners and organizations can implement.
Prospective Randomized Double-blind Placebo Controlled Trial of Recombinant Human Erythropoietin Administration to Reduce Blood Transfusions in Anemic Pediatric Intensive Care Patients The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG. Apr, 2006 | Pubmed ID: 23118648 The purpose of this study was to determine if the number of red blood cell (RBC) transfusions anemic pediatric intensive care unit patients receive could be reduced by the prophylactic administration of recombinant human erythropoietin (rHuEPO).
Implementazione Di Un Servizio Di Assistenza Farmaceutica Management Di Peso The Annals of Pharmacotherapy. Feb, 2007 | Pubmed ID: 17284503 L'obesità, un'epidemia nazionale, è una delle principali cause di morbilità prevenibile e mortalità negli Stati Uniti. I farmacisti possono svolgere un ruolo fondamentale nella gestione del peso corporeo. Peso gestione servizi offre l'opportunità di aumentare la sensibilizzazione del pubblico di assistenza farmaceutica e attrarre pazienti ai programmi della farmacia.
Use of Personal Digital Assistants for Documentation of Pharmacists' Interventions: a Literature Review American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. Jul, 2007 | Pubmed ID: 17617503 The literature describing pharmacists' use of personal digital assistants (PDAs) as intervention documentation tools in health systems is reviewed.
Economic Considerations in the Treatment of Invasive Aspergillosis: a Review of Voriconazole Pharmacoeconomic Studies ClinicoEconomics and Outcomes Research : CEOR. 2009 | Pubmed ID: 21935305 Invasive aspergillosis is a life-threatening fungal infection predominately affecting immunocompromised individuals. The incidence of inpatient-treated aspergillosis cases in the US is estimated to be between 3.02 and 3.80 per 10,000 hospitalized patients. The estimated difference in hospital costs of patients with an aspergillosis infection is US$36,867 to US$59,356 higher than those of patients without the infection. Voriconazole is a synthetic, broad spectrum triazole antifungal agent, with FDA-approved indications for the treatment of invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients, invasive candidiasis, and infections due to Scedosporium apiospermum and Fusarium species in patients refractory to or intolerant of other therapy. Eight cost-effectiveness analyses, one cost-minimization analysis, and one cost analysis were identified from a Medline search. The 10 pharmacoeconomic analyses were conducted in six different countries comparing voriconazole to conventional amphotericin B, liposomal amphotericin B, itraconazole, and caspofungin. All the cost-effectiveness and cost-minimization analyses identified voriconazole as the most cost-effective therapy. The cost analysis demonstrated voriconazole cost-savings. While the acquisition costs of voriconazole are higher than those of conventional amphotericin B, the toxicity profile and rate of treatment success associated with voriconazole result in lower total treatment costs per successfully treated patient.
A Health Policy Course Based on Fink's Taxonomy of Significant Learning American Journal of Pharmaceutical Education. Feb, 2011 | Pubmed ID: 21451768 To incorporate Fink's Taxonomy of Significant Learning into a course and determine whether doing so increased students' knowledge of and interest in healthcare policy.